Alpha Tau Medical (NASDAQ:DRTS) Stock Price Down 9.4% – Time to Sell?

Alpha Tau Medical Ltd. (NASDAQ:DRTS)’s stock price traded down 9.4% on Friday . The stock traded as low as $9.78 and last traded at $9.93. 276,319 shares were traded during trading, a decline of 40% from the average session volume of 462,684 shares. The stock had previously closed at $10.96.

Alpha Tau Medical News Roundup

Here are the key news stories impacting Alpha Tau Medical this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating on Alpha Tau Medical and maintained a $15.00 price target, which is above the stock’s recent trading range and can bolster investor confidence. Alpha Tau Medical (NASDAQ:DRTS) Receives “Buy” Rating from HC Wainwright
• Neutral Sentiment: The firm also published updated earnings estimates for 2026 and 2027, keeping forecasts in a similar loss-making range, which signals continued expectations for gradual progress rather than a major change in the business outlook.
• Negative Sentiment: HC Wainwright cut its EPS estimates for Q2 2026, Q3 2026, Q4 2026, and FY2026, reflecting somewhat softer short-term profitability expectations.

Analyst Ratings Changes

DRTS has been the subject of several research analyst reports. Piper Sandler lifted their target price on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Citigroup lifted their target price on Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Alpha Tau Medical in a research note on Wednesday. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $11.50.

Alpha Tau Medical Stock Down 5.9%

The stock has a market capitalization of $907.74 million, a PE ratio of -15.39 and a beta of 1.11. The firm’s fifty day moving average is $7.96 and its 200-day moving average is $6.52. The company has a quick ratio of 7.45, a current ratio of 7.79 and a debt-to-equity ratio of 0.09.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). On average, equities research analysts predict that Alpha Tau Medical Ltd. will post -0.56 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Trifecta Capital Advisors LLC purchased a new position in Alpha Tau Medical in the fourth quarter valued at about $48,000. Envestnet Asset Management Inc. purchased a new position in Alpha Tau Medical in the third quarter valued at about $62,000. Bank of America Corp DE increased its holdings in Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after buying an additional 21,677 shares in the last quarter. Wells Fargo & Company MN increased its holdings in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after buying an additional 17,500 shares in the last quarter. Finally, Principal Financial Group Inc. purchased a new position in Alpha Tau Medical in the first quarter valued at about $132,000. 2.65% of the stock is owned by hedge funds and other institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.